Improved Survival, Quality of Life, and Quality-Adjusted Survival in Breast Cancer Patients Treated With Efaproxiral (Efaproxyn) Plus Whole-Brain Radiation Therapy for Brain Metastases

2007 ◽  
Vol 30 (6) ◽  
pp. 580-587 ◽  
Author(s):  
Charles Scott ◽  
John Suh ◽  
Baldassarre Stea ◽  
Abdenour Nabid ◽  
John Hackman
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Radiation Therapy ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Whole Brain ◽  
Whole Brain Radiation ◽  
Brain Radiation

Whole-brain radiation therapy in breast cancer patients with brain metastases

2010 ◽  
Vol 7 (11) ◽  
pp. 632-640 ◽  
Author(s):  
Cyrus Chargari ◽  
François Campana ◽  
Jean-Yves Pierga ◽  
Lionel Védrine ◽  
Damien Ricard ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Whole Brain Radiation Therapy ◽  
Breast Cancer Patients ◽  
Whole Brain ◽  
Whole Brain Radiation ◽  
Brain Radiation

Phase III Study of Efaproxiral As an Adjunct to Whole-Brain Radiation Therapy for Brain Metastases

2006 ◽  
Vol 24 (1) ◽  
pp. 106-114 ◽  
Author(s):  
John H. Suh ◽  
Baldassarre Stea ◽  
Abdenour Nabid ◽  
John J. Kresl ◽  
André Fortin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Response Rates ◽  
Supplemental Oxygen ◽  
Breast Cancer Patients ◽  
Whole Brain ◽  
Whole Brain Radiation ◽  
Brain Radiation

Purpose To determine whether efaproxiral, an allosteric modifier of hemoglobin, improves survival in patients with brain metastases when used as an adjunct to whole-brain radiation therapy (WBRT). Patients and Methods Patients with brain metastases from solid tumors and a Karnofsky performance score of ≥ 70 were randomly assigned to receive WBRT with supplemental oxygen and either efaproxiral at 75 or 100 mg/kg (efaproxiral arm) or no efaproxiral (control arm). The primary end point was survival. Results The study consisted of 515 eligible patients (efaproxiral arm, n = 265; control arm, n = 250). The median survival time (MST) was 5.4 months for the efaproxiral arm versus 4.4 months for the control arm (hazard ratio [HR] = 0.87; P = .16). For the subgroup of patients with non–small-cell lung cancer (NSCLC) or breast cancer, the MST was 6.0 and 4.4 months, respectively (HR = 0.82; P = .07). Cox multiple regression analysis demonstrated a significant reduction in the risk of death for the efaproxiral arm in both primary populations. Further analysis indicated that the benefit may be restricted to the subgroup of patients with breast cancer. Response rates (radiographic complete response plus partial response) improved by 7% (P = .10) and 13% (P = .01) for all patients and for NSCLC and breast cancer patients in the efaproxiral arm, respectively. The most common severe adverse event in patients treated with efaproxiral was hypoxemia, which was reversible and effectively managed with supplemental oxygen in most patients. Conclusion The addition of efaproxiral, a noncytotoxic radiation sensitizer, to WBRT may improve response rates and survival in patients with brain metastases, particularly metastases from breast cancer. A confirmatory trial for breast cancer patients has been initiated.

Sign in / Sign up

Export Citation Format

Share Document